BMC Gastroenterology最新文献

Background: Those who have severe fibrosis (F2 ≥ 2 stage) are at the greatest risk for the advancement of the illness among non-alcoholic fatty liver patients. To forecast the non-alcoholic steatohepatitis (NASH) probability accompanied by significant fibrosis, we propose to develop and validate a nomogram liver imaging reporting and data system, providing robust evidence for preventing and treating clinical liver diseases.

Methods: The study used SD rats to create a model of hepatic steatosis and fibrosis by feeding them a high-fat diet and injecting Ccl4 subcutaneously. Radiomics characteristics were derived from two-dimensional liver ultrasound images of the rats, and a radiomics model was constructed, with rad-scores calculated accordingly. Univariate and multivariate logistic regression was employed to ascertain the clinical characteristics of rats and liver elasticity values, aiming to establish a clinical model. Ultimately, a clinical radiomics model was created by integrating the rad-score from the radiomics model with independent clinical characteristics from the clinical model. A forest plot was generated to depict this integration. The forest plot's performance was assessed by the use of the area under the receiver operating characteristic (ROC) curve (AUC), decision curve analysis, and calibration curve.

Results: The areas under the receiver operating characteristic curve (AUC) for the training set and validation set of the clinical radiomics model were 0.986 and 0.971, respectively. Decision curve analysis showed that the clinical radiomics model had the highest net benefit across most threshold probability ranges.

Conclusion: The nomogram and clinical radiomics model, which consists of clinical characteristics, real-time shear wave elastography, and radiomics, provide excellent predictive capability in assessing the likelihood of fibrotic NASH.

Background: Current data indicate that supplements such as folic acid play a significant role in treating chronic atrophic gastritis (CAG). However, no meta-analysis article evaluates its efficacy comprehensively. Therefore, we conducted a meta-analysis to compare the effectiveness and safety of folic acid in the treatment of CAG with Helicobacter pylori (H. pylori) infection.

Methods: Using a systematic review method, consider randomized controlled trials (RCT), including clinical trial reports, unpublished clinical trial data, and conference papers. A comprehensive search of the literature was conducted from all years up to June 2024. We searched PubMed, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), Vip, and Wanfang databases. Data were extracted using a pre-designed extraction tool and analysis was undertaken using RevMan5.4 and STAT15.1. Efficacy and safety outcomes were evaluated using risk ratio (RR) and 95% confidence intervals (CI).

Results: 16 randomized controlled trials with 1364 patients were included. Compared with conventional therapy, folic acid therapy had a higher total effective rate (95.09% vs.79.06%, pooled RR = 1.19, 95% CI: 1.12-1.26, p < 0.00001) and lower incidence of adverse events (11.64% vs. 14.04%, RR = 0.86, 95% CI: 0.46-1.60, p = 0.64). Moreover, folic acid can better improve gastric function and repair gastric mucosa (MD = 27.20, 95%CI:23.84-30.56, p < 0.00001).

Conclusions: For HP-related CAG, anti-HP treatment and folic acid supplementation should be started as early as possible. Gastric mucosal protective agents can improve the curative effect and can be selected according to the condition of patients with obvious adverse reactions. Our study provided evidence for their potential clinical use in the management of CAG. However, CAG-related studies in other countries and regions need to be further studied.

Registration: The logn number of our Meta-analysis on PROSPERO is 42,024,571,785.

Background: Gallstones are a prevalent health issue. Recent studies have revealed that blood pressure (BP) may affect gallstone formation. This study assessed the association between hypertension (HTN) and both the prevalence of gallstones and the age at first cholecystectomy among U.S. adults.

Methods: Data were extracted from the National Health and Nutrition Examination Survey (NHANES) database from 2017 to 2020. Weighted logistic and linear regression analyses and subgroup analyses were employed to investigate the relationships between HTN, gallstone disease (GD), and age at first cholecystectomy. Additionally, this study employed generalized additive models (GAM) and smooth-fitting curves to delineate the relationships. The two-piecewise linear regression model and logarithmic likelihood ratio test elucidated the inflection point of systolic blood pressure (SBP) on the age at first cholecystectomy.

Results: The study included 7,532 participants aged over 20 years. Of these, 817 reported a history of cholecystectomy, and 781 reported a history of gallstones. After adjustment for age, gender, race, diabetes, and hypercholesterolemia, HTN was significantly associated with gallstones in individuals aged 48 years (OR = 1.39; 95% CI: 1.03, 1.88). SBP was positively correlated with the age at first cholecystectomy (β = 0.20, 95% CI: 0.13, 0.26). When examining the correlation between SBP and age at surgery, age was first positively and then negatively correlated with BP, with 170 as an inflection point. We carried out subgroup analyses to evaluate the robustness of the link between HTN and cholecystectomy. The results revealed a consistent positive association between HTN and cholecystectomy across these variables (p > 0.05).

Conclusion: The study found a correlation between BP and the prevalence of gallstones in individuals aged 42 years and older and a positive association between SBP and the age at first cholecystectomy. While causality cannot be confirmed, these findings may assist in identifying early risk groups for GD and early cholecystectomy, thereby enhancing risk stratification and potentially reducing screening costs.

Purpose: The aim of the study was to explore long-term experiences of transanal irrigation (TAI) in patients with major low anterior resection syndrome (LARS).

Methods: The study included a qualitative and quantitative analysis of patients who developed major LARS after rectal cancer surgery between 2016 and 2019 and have undergone treatment with TAI. The patients received questionnaires. Mean scores were calculated with time-to-deterioration. Individual semi-structured interviews were performed and analyzed, according to Graneheim and Lundman with patients who performed TAI regularly for more than one year.

Results: In total 28 out of 39 patients responded to the questionnaires and 16 patients participated in the interviews. At mean 6-years follow-up, a 9.4 points difference in mean LARS score was obtained, (21.2 vs. 30.7) indicating less LARS symptoms in favor of the TAI treatment. Patients in the TAI group used less loperamide compared to the control group (36% vs. 79%). The use of bulky agents was similar. The interview text rendered into three main categories: regaining control in everyday life, need for structure and planning and becoming familiar with the procedure.

Conclusions: Treatment with TAI showed the potential to improve the quality of life of patients with major LARS. The improvements in their general well-being were valued over adjustments and time spent on TAI.

Implications for cancer survivors: Bowel dysfunction remains after 6-years with lower LARS scores favoring the TAI treatment. In the absence of a definitive treatment, survivors of rectal cancer coping with LARS have shown appreciation of the TAI treatment.

Objective: This study aimed to analyze the characteristics of patients undergoing percutaneous liver biopsies and investigate the pathological manifestations of four major liver diseases across different age groups.

Methods: A retrospective analysis was conducted of 4,717 liver pathology reports from 2009 to 2024. The study population comprised 4,188 patients who underwent liver biopsies, with 408 patients receiving two biopsies and 50 patients who underwent three or more procedures. Most of biopsies (4,171) were performed between 2013 and 2023. Disease categorization, temporal distribution, and pathological manifestations across different age groups were assessed employed descriptive statistics, trend analyses, and graphical representations.

Results: Since 2020, a gradual increase has been observed in the proportion of cases involving concurrent hepatitis B complicated by metabolic-associated steatohepatitis (MASLD), along with an elevation in the incidence of MASLD alone. Pathological manifestations varied considerably across different age groups. Patients with hepatitis B complicated by MASLD exhibited disease exacerbation in middle age, with both liver inflammation and fibrosis grading worsening as age advanced. Furthermore, within the same age bracket, the severity of inflammation and the extent of fibrosis were more pronounced in cases where chronic hepatitis B was combined with MASLD compared to those with isolated chronic hepatitis B or MASLD.

Conclusion: This study offers a comprehensive analysis of the characteristics and pathological manifestations of patients who underwent percutaneous liver biopsies over a 15-year period. The findings underscore the varying pathological manifestations across different age groups for the four major liver diseases and emphasize the necessity for tailored therapeutic interventions, particularly for patients with concurrent hepatitis B and MASLD, as antiviral therapy alone may be inadequate. Further research is warranted to explore optimal management strategies for these patient subpopulations.

Objective: To evaluate the therapeutic impact of reduced glutathione combined with entecavir on liver function, fibrosis, and HBV-DNA clearance in chronic hepatitis B patients.

Methods: This was a randomized controlled trial. This study included 90 patients diagnosed with chronic hepatitis B, who were randomly divided into two groups (observation group and control group) using a random number table, with 45 patients in each group. The control group received standard entecavir treatment (0.5 mg/time, once a day, continuous treatment for 3 months), while the observation group received a combination therapy of reduced glutathione and the standard entecavir treatment. Liver function markers (ALT, TBIL, AST, ALB), fibrosis markers (HA, PC III, LN), and liver fibrosis grades were assessed pre-and post-treatment. HBV-DNA negative conversion rates were recorded at 4, 12, 24, and 48 weeks. The incidence of adverse reactions, including nausea, vomiting, headache, and mild gastric discomfort, was recorded and compared between the two groups during the treatment period.

Results: ALT decreased from 348.96 ± 31.47 U/L to 31.11 ± 9.78 U/L in the observation group and from 347.90 ± 31.40 U/L to 56.90 ± 16.32 U/L in the control group (P < 0.05). TBIL decreased from 61.78 ± 4.94 µmol/L to 18.82 ± 2.93 µmol/L in the observation group and from 61.32 ± 4.93 µmol/L to 26.70 ± 4.44 µmol/L in the control group (P < 0.05). ALB increased from 29.65 ± 0.94 g/L to 48.76 ± 4.85 g/L in the observation group and from 29.77 ± 0.90 g/L to 34.12 ± 0.84 g/L in the control group (P < 0.05). The observation group showed greater reductions in HA, PC III, and LN, and improved liver fibrosis grades (P < 0.05). HBV-DNA negative conversion rates in the observation group were 15.56%, 35.56%, 60.00%, and 68.89% at 4, 12, 24, and 48 weeks, respectively, compared to 2.22%, 6.67%, 17.78%, and 42.22% in the control group (P < 0.05). Adverse reaction rates were 8.89% in the observation group and 20.00% in the control group (P > 0.05).

Conclusion: Reduced glutathione combined with entecavir significantly improves liver function, reduces liver fibrosis, and enhances HBV-DNA clearance in chronic hepatitis B patients without increasing adverse reactions.

Background: Cirrhosis is a leading cause of mortality in patients with chronic liver disease (CLD). The rapid development of metabolomic technologies has enabled the capture of metabolic changes related to the progression of cirrhosis.

Methods: This study used proton nuclear magnetic resonance (1 H-NMR) serum metabolomics data from the UK Biobank (UKB) and employed elastic net-regularized Cox proportional hazards models to explore the role of metabolomics in cirrhosis risk stratification in patients with CLD. Metabolomic data were integrated with aspartate aminotransferase to platelet ratio index (APRI) and fibrosis-4 score (FIB-4) to construct predictive models for cirrhosis risk. The model performance was assessed in both the derivation and validation cohorts.

Results: A total of 2,738 eligible patients were included in the analysis. Several metabolites showed an independent association with cirrhosis events (68 out of 168 metabolites after adjustment for age and sex, and 21 out of 168 metabolites after full adjustment). The integration of metabolomics with FIB-4 improved the predictive performance compared to FIB-4 alone (Harrell's C: 0.717 vs. 0.696, ΔC = 0.021, 95% confidence interval [CI] 0.014-0.028, Net Reclassification Improvement [NRI]: 0.504 [0.488-0.520]). Similarly, the combination of metabolomics with APRI also improved predictive performance compared to APRI alone (Harrell's C: 0.747 vs. 0.718, ΔC = 0.029, 95% CI 0.022-0.035, NRI: 0.378 [0.366-0.389]). Key metabolites, including branched-chain amino acids (BCAAs), lipids, and markers of oxidative stress, were identified as significant predictors. Pathway enrichment analysis revealed that disruptions in lipid and amino acid metabolism play a central role in the progression of cirrhosis.

Conclusion: 1 H-NMR serum metabolomics significantly improves the prediction of cirrhosis risk in patients with CLD. The APRI + Metabolomics model demonstrated strong discriminatory power, with key metabolites involved in fatty acid and amino acid metabolism, providing a promising tool for the early screening of cirrhosis risk.

Background: Sarcopenia is common in chronic pancreatitis (CP) and has been associated with unfavorable outcomes; however, it is not well studied in acute pancreatitis (AP).

Aims: To evaluate risk factors for sarcopenia among individuals with AP or CP.

Methods: A cross sectional analysis was performed among subjects with AP or CP seen in a tertiary care Pancreas Clinic. TeraRecon software was used to calculate the cross-sectional area of skeletal muscle, visceral fat, and subcutaneous fat at the level of the L3 vertebrae. Sarcopenia was classified using sex-specific skeletal muscle index. Univariate and multivariate logistic regressions were performed to assess differences between groups and associations with sarcopenia.

Results: A total of 49 subjects with AP and 54 subjects with CP were included. Sarcopenia was more frequently observed in CP compared to AP (83.3% vs. 46.9%, p < 0.001). The multivariate logistic regression demonstrated CP, male sex, increased age, and decreased subcutaneous fat were independently associated with sarcopenia.

Conclusion: Sarcopenia is observed in both CP and AP. In addition to traditional risk factors (including male sex, older age, and decreased subcutaneous fat), CP is independently associated with sarcopenia. Further investigations are necessary to gain deeper insights into sarcopenia pathogenesis, which could inform potential intervention strategies.

Background: Detecting and demarcating early gastric cancers (EGC) after eradication therapy of Helicobacter pylori (H. pylori) is a challenging task due to the fact that the lesion's surface is covered with gastritis-like tissue (non-neoplastic epithelium covering the cancerous tissue). However, our study aimed to investigate the endoscopic alterations of EGC within 3 months after eradication, which has not been reported clearly yet.

Methods: Consecutive EGC patients who underwent two gastroscopies (one with H. pylori infection and another within 3 months after successful H. pylori eradication) were enrolled. The endoscopic photographs were evaluated for the endoscopic features and confidence level of demarcation line (DL), invasion depth, and histopathological classification by three highly experienced endoscopists. The DL estimated by endoscopy was compared with that of postoperative pathological examination.

Results: 45 pairs of EGC cases before and after eradication were enrolled. All the confidence level of DL (High confidence: 15.6% vs. 93.3%, p value = 0.000) and invasion depth (High confidence: 37.8% vs. 80.0%, p value = 0.000) and histopathological classification (High confidence: 31.1% vs. 91.1%, p value = 0.000) were significantly improved after eradication. A higher confidence level of DL before eradication was correlated with severe atrophy score (p value = 0.036). The inter-observer agreements for DL, invasion depth, and histopathological classification were 0.85 and 0.75 and 0.78, respectively.

Conclusions: DL of EGC becomes much more apparent after eradication in the short-term. Eradication therapy is necessary even shortly prior to the procedure of endoscopic submucosal dissection (ESD) to help precise pre-procedure diagnosis and avoid incomplete resection.

Objective: This review assesses the progress of NLP in gastroenterology to date, grades the robustness of the methodology, exposes the field to a new generation of authors, and highlights opportunities for future research.

Design: Seven scholarly databases (ACM Digital Library, Arxiv, Embase, IEEE Explore, Pubmed, Scopus and Google Scholar) were searched for studies published between 2015 and 2023 that met the inclusion criteria. Studies lacking a description of appropriate validation or NLP methods were excluded, as were studies ufinavailable in English, those focused on non-gastrointestinal diseases and those that were duplicates. Two independent reviewers extracted study information, clinical/algorithm details, and relevant outcome data. Methodological quality and bias risks were appraised using a checklist of quality indicators for NLP studies.

Results: Fifty-three studies were identified utilising NLP in endoscopy, inflammatory bowel disease, gastrointestinal bleeding, liver and pancreatic disease. Colonoscopy was the focus of 21 (38.9%) studies; 13 (24.1%) focused on liver disease, 7 (13.0%) on inflammatory bowel disease, 4 (7.4%) on gastroscopy, 4 (7.4%) on pancreatic disease and 2 (3.7%) on endoscopic sedation/ERCP and gastrointestinal bleeding. Only 30 (56.6%) of the studies reported patient demographics, and only 13 (24.5%) had a low risk of validation bias. Thirty-five (66%) studies mentioned generalisability, but only 5 (9.4%) mentioned explainability or shared code/models.

Conclusion: NLP can unlock substantial clinical information from free-text notes stored in EPRs and is already being used, particularly to interpret colonoscopy and radiology reports. However, the models we have thus far lack transparency, leading to duplication, bias, and doubts about generalisability. Therefore, greater clinical engagement, collaboration, and open sharing of appropriate datasets and code are needed.